Navigation Links
Sunesis in Medical Technology

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

...ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research

...ch (AACR) being held April 12-16 in San Diego, CA. sunesis has built a portfolio of product candidates in onc...ibit Hall B-F, San Diego Convention Center About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...rapeutics for oncology and other serious diseases. sunesis has built a broad product candidate portfolio thro...

Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

... Center in Atlanta, Georgia. On December 10, 2007, sunesis management will host a conference call for investo... a.m. to 7:00 p.m. Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at http://www.sunesis.com . Please log on...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

...- /ADVANCE FOR RELEASE AT 3:30 P.M. EDT, TODAY/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical...nt progressed within 60 days of initial response. sunesis plans to enroll approximately 55 patients in this ...hirty-one patients have been enrolled to date, and sunesis expects to complete enrollment and present additio...

Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314

...ug-resistant models. About SNS-314 Discovered by sunesis using the company's discovery platform, SNS-314 is...le in the abnormal proliferation of tumors. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

..., Calif., March 20, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. , presented non-clinical dat...er Therapies (TAT 2007) meeting held in Amsterdam, sunesis researchers presented results showing SNS-314's an...of this year. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...

Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research

..., Calif., April 13, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com... 7, board #1. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

...l lymphoma. Non-clinical studies were conducted by sunesis evaluating SNS-032's mechanism of action and in vi...ce apoptosis. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

...O, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com...session. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...O, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. presented positive data from...odels while sparing normal hematopoietic recovery. sunesis plans to initiate a Phase 1b clinical trial of SNS...NS-032 to Flavopirodol In a second presentation, sunesis reported the results of studies evaluating its cyc...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

...O, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that Eric Bj...ss the webcast of the presentation by visiting the sunesis website at sunesis website for two weeks until July 26, 2007. Optio...
Other Tags
(Date:4/17/2014)... If a restaurant ... he can expect his premises to be trashed. Warnings like ... is enough to make restaurant owners pay up. Similarly, mafia-like ... in other birds, nests. If the host birds throw the ... destroying the entire nest. Consequently, it is beneficial for hosts ...
(Date:4/17/2014)... novel method to help kidney stone sufferers ensure ... possible., Kidney stones represent a major medical problem ... untreated, apart from being particularly painful, they can ... many patients treated successfully, stone recurrence is also ... to diagnosis and treatment needs to be identified ...
(Date:4/17/2014)... in the Cell Press journal Current Biology ... rather novel sex lives. The Brazilian insects, which represent ... Neotrogla , are the first example of an animal ... been identified in several different animals, Neotrogla ... is also reversed," says Kazunori Yoshizawa from Hokkaido University ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3In sex-reversed cave insects, females have the penises 2
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
Other Contents